Clinical Trial Results:
An open label dose adjustment and phase II study of E7070 in combination with capecitabine:
Part 1: to determine the recommended dose of the combination
Part 2: to determine the efficacy of the combination in patients with metastatic colorectal cancer (CRC) who are resistant to or unsuitable for treatment with 5-fluorouracil and irinotecan and/or oxaliplatin
Summary
|
|
EudraCT number |
2004-002597-33 |
Trial protocol |
DE |
Global completion date |
06 Feb 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Aug 2019
|
First version publication date |
18 Aug 2019
|
Other versions |
|
Summary report(s) |
CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.